P226 EMPAGLIFLOZIN IS ABLE TO REDUCE COLLAGEN DEPOSITION IMPROVING HEART FUNCTION IN MYOCARDIAL INFARCTED RATS

Cardiovascular diseases, particularly Acute Myocardial Infarction (AMI), are the leading cause of death worldwide. Studies show that empagliflozin improves cardiac function and outcomes in patients with heart failure. This study hypothesizes that different doses of empagliflozin (3 mg/kg and 10 mg/kg) affect collagen deposition and cardiac function differently. Male Wistar rats were divided into four groups: control (Ctrl), infarcted (AMI), infarcted treated with empagliflozin 3 mg/kg (AMI+EMPA3), and infarcted treated with empagliflozin 10 mg/kg (AMI+EMPA10). Infarcted groups underwent left coronary artery occlusion. Treated groups received empagliflozin for 14 days via oral gavage. Echocardiographic evaluation was followed by euthanasia and tissue collection. Collagen deposition was assessed histologically and stained with picrosirius red, with area calculations done. Data were analyzed using the 1-way ANOVA test. Echocardiographic results showed an improvement in diastolic function index (E’/A’) in the AMI+EMPA10 group (1.654 ± 0.3) in relation to the Ctrl (0.98 ± 0.5), AMI (0.58 ± 0.1) and AMI+EMPA3 (1.02 ± 0.4). Systolic function, measured by ejection fraction, was reduced in AMI (30.14 ± 9.7%) and AMI+EMPA3 (33.68 ± 13.2%) compared to Ctrl (77.09 ± 8.1%). The AMI+EMPA10 group showed improved ejection fraction (50.69 ± 14.5%). Fractional area change showed similar patterns (Ctrl: 61.18 ± 5.7; AMI: 23.94 ± 5.7%; AMI+EMPA3: 27.39 ± 7.2%; AMI+EMPA10: 38.46 ± 7.1%). Histology revealed no difference in total left ventricle area among groups, but collagen area was increased in AMI (81.30 ± 16.2 mm 2 ) and AMI+EMPA3 (86.64 ± 15.3 mm 2 ) compared to Ctrl (62.89 ± 16.2 mm 2 ), but not in AMI+EMPA10 (77.68 ± 8.5 mm 2 ). In conclusion, empagliflozin treatment improved left ventricular diastolic and systolic function dose-dependently and reduced collagen deposition in infarcted rats. Supported by: CNPq 312962/2020-7

Authors

Institutions

Publication Details

Journal
Journal of Hypertension
Published
2024-09-01
DOI
https://doi.org/10.1097/01.hjh.0001063776.57593.3d
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P226 EMPAGLIFLOZIN IS ABLE TO REDUCE COLLAGEN DEPOSITION IMPROVING HEART FUNCTION IN MYOCARDIAL INFARCTED RATS

Fernanda Marciano Consolim‐Colombo, Maria Cláudia Irigoyen, Luciano de Figueiredo Borges, Bruno Durante da Silva et al.
Journal of Hypertension
Diabetes Treatment and Management
article

P226 EMPAGLIFLOZIN IS ABLE TO REDUCE COLLAGEN DEPOSITION IMPROVING HEART FUNCTION IN MYOCARDIAL INFARCTED RATS

Fernanda Marciano Consolim‐Colombo, Maria Cláudia Irigoyen, Luciano de Figueiredo Borges, Bruno Durante da Silva, Nathalia Juocys Dias Moreira, Biologist Maikon Barbosa, Kátia De Angelis, Biologist Leandro Souza, Msc Bruno Nascimento-Carvalho, Biologist Antonio Nascimento, Biologist Andressa Godoy
article en

Abstract

Cardiovascular diseases, particularly Acute Myocardial Infarction (AMI), are the leading cause of death worldwide. Studies show that empagliflozin improves cardiac function and outcomes in patients with heart failure. This study hypothesizes that different doses of empagliflozin (3 mg/kg and 10 mg/kg) affect collagen deposition and cardiac function differently. Male Wistar rats were divided into four groups: control (Ctrl), infarcted (AMI), infarcted treated with empagliflozin 3 mg/kg (AMI+EMPA3), and infarcted treated with empagliflozin 10 mg/kg (AMI+EMPA10). Infarcted groups underwent left coronary artery occlusion. Treated groups received empagliflozin for 14 days via oral gavage. Echocardiographic evaluation was followed by euthanasia and tissue collection. Collagen deposition was assessed histologically and stained with picrosirius red, with area calculations done. Data were analyzed using the 1-way ANOVA test. Echocardiographic results showed an improvement in diastolic function index (E’/A’) in the AMI+EMPA10 group (1.654 ± 0.3) in relation to the Ctrl (0.98 ± 0.5), AMI (0.58 ± 0.1) and AMI+EMPA3 (1.02 ± 0.4). Systolic function, measured by ejection fraction, was reduced in AMI (30.14 ± 9.7%) and AMI+EMPA3 (33.68 ± 13.2%) compared to Ctrl (77.09 ± 8.1%). The AMI+EMPA10 group showed improved ejection fraction (50.69 ± 14.5%). Fractional area change showed similar patterns (Ctrl: 61.18 ± 5.7; AMI: 23.94 ± 5.7%; AMI+EMPA3: 27.39 ± 7.2%; AMI+EMPA10: 38.46 ± 7.1%). Histology revealed no difference in total left ventricle area among groups, but collagen area was increased in AMI (81.30 ± 16.2 mm 2 ) and AMI+EMPA3 (86.64 ± 15.3 mm 2 ) compared to Ctrl (62.89 ± 16.2 mm 2 ), but not in AMI+EMPA10 (77.68 ± 8.5 mm 2 ). In conclusion, empagliflozin treatment improved left ventricular diastolic and systolic function dose-dependently and reduced collagen deposition in infarcted rats. Supported by: CNPq 312962/2020-7

Journal of HypertensionVol. 42(Suppl 3)
Hospital Universitário da Universidade de São Paulo (BR), Universidade Federal de São Paulo (BR)
Openalex Percentile: Top 76%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.